ctDNA-Guided Therapy in Bladder Cancer — Ready?

15th Jan, 2026

Hematology/Oncology

The New England Journal of Medicine

Liquid-biopsy analysis for circulating tumor DNA (ctDNA) has the potential to transform cancer care through personalized, noninvasive disease monitoring. In bladder cancer, ctDNA is a strong prognostic biomarker after cystectomy and may guide adjuvant treatment decisions. Retrospective and prospective studies show that ctDNA positivity is linked to an increased risk…

Published By: The New England Journal of Medicine

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Heads or the Tail?

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Biting the Tail of CAR-T for Relapsed Multiple Myeloma

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Gene Therapy for Nephropathic Cystinosis

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Hematology/Oncology

11th Mar, 2026

The New England Journal of Medicine

ctDNA-Guided Therapy in Bladder Cancer — Ready?

Related Articles

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Heads or the Tail?

Biting the Tail of CAR-T for Relapsed Multiple Myeloma

Gene Therapy for Nephropathic Cystinosis

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

ctDNA-Guided Therapy in Bladder Cancer — Ready?

Related Articles

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

Heads or the Tail?

Biting the Tail of CAR-T for Relapsed Multiple Myeloma

Gene Therapy for Nephropathic Cystinosis

Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Hitting the Mark — Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors